Foresite Capital Management II’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Foresite Capital Management II’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-877,134	Closed	-$3.41M	–	16
2017 Q1	$3.41M	Sell	877,134 -17,561	-2%	-$61.7K	1.46%	7
2016 Q4	$3.34M	Sell	894,695 -5,460	-0.6%	-$22.5K	1.68%	6
2016 Q3	$3.74M	Hold	900,155	–	–	1.78%	7
2016 Q2	$4.18M	Buy	900,155 +12,354	+1%	+$42.9K	2.86%	9
2016 Q1	$2.93M	Buy	887,801 +13,800	+2%	+$45K	1.43%	14
2015 Q4	$2.98M	Buy	874,001 +165,669	+23%	+$654K	1%	18
2015 Q3	$2.58M	Hold	708,332	–	–	0.78%	19
2015 Q2	$3.52M	Hold	708,332	–	–	1.24%	17
2015 Q1	$5.69M	Buy	+708,332	New	+$6.7M	3.37%	7

Other funds holding NVET

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KAM

Kassirer Asset Management Toronto, Ontario, Canada $4.07M AUM 49.71% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

SMC

S. Muoio & Co New York $75.7M AUM 42.51% 1-Year Est. Return

Foresite Capital Management II's NVET Position: Q2 2017 in Review

Foresite Capital Management II sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q2 2017, closing a stake of 877,134 shares — an estimated $3.41M sold.

Foresite Capital Management II first reported a position in NVET in Q1 2015 and held it in 9 quarters. The position peaked at $5.69M in Q1 2015. 20 funds tracked by Wall St. Rank hold NVET as of Q2 2017.

Foresite Capital Management II reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Foresite Capital Management II sold 877,134 Nexvet Biopharma plc Ordinary Shares shares in Q2 2017, an estimated $3.41M.
Foresite Capital Management II first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 9 quarters.
Foresite Capital Management II's Nexvet Biopharma plc Ordinary Shares position peaked at $5.69M in Q1 2015.
20 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q2 2017.

Based on Foresite Capital Management II's 13F filing for Q2 2017, filed 14 Aug 2017.